Carrick Therapeutics Limited: Clinical Trials

6 trials sponsored by Carrick Therapeutics Limited, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 recruiting. 5 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 3, Recruiting 2
Phase 25Completed 4, Recruiting 1

Follow Carrick Therapeutics Limited: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy - Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
Phase 1RecruitingUniversity of Washington152026-10-152026-09-21
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg) - Solid Malignancies
Phase 1 / Phase 2RecruitingCarrick Therapeutics Limited502024-08-162026-09-03
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
vepdegestrant, Samuraciclib - Breast Cancer
Phase 1 / Phase 2CompletedPfizer112024-01-102026-10-02
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
Samuraciclib, Fulvestrant - Metastatic Breast Cancer, Locally Advanced Breast Cancer
Phase 2CompletedCarrick Therapeutics Limited602023-11-162025-12-26
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
Samuraciclib, Elacestrant Dihydrochloride - Metastatic Breast Cancer, Locally Advanced Breast Cancer
Phase 1 / Phase 2CompletedCarrick Therapeutics Limited492023-10-092026-03-23
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
CT7001, Fulvestrant - Advanced Solid Malignancies
Phase 1 / Phase 2CompletedCarrick Therapeutics Limited1242017-11-142026-06-23

Conditions studied

Breast Neoplasms (3)  ·  Neoplasms (1)

Interventions

Fulvestrant (2)  ·  RAD1901 (1)  ·  Specimen Handling (1)

Countries

United States (6)  ·  United Kingdom (3)  ·  France (2)  ·  Spain (2)  ·  Belgium (1)  ·  Hungary (1)  ·  Italy (1)  ·  Mexico (1)  ·  Turkey (Türkiye) (1)

Top investigators

Andrew Coveler, MD (1)  ·  Matthew Krebs, MBChB PhD (1)

Results publications

PMID 32385714, PMID 37488191

NIH funding

2023 (3), 2017 (1)